Results 161 to 170 of about 210,637 (269)

Effectiveness of 12-month GnRH antagonist treatment for endometriosis-associated pain: driven by reduction in uterine bleeding? [PDF]

Hum Reprod Open
D'Hooghe TM.
europepmc   +1 more source

Seminal Plasma Exosomal miRNA Profiling Reveals hsa‐miR‐7‐5p as a Key Regulator of Sperm Motility in Asthenozoospermia

Andrology, Volume 14, Issue 7, Page 2166-2179, October 2026.
ABSTRACT Background Asthenozoospermia is a significant contributing factor to male infertility. Accumulating evidence indicates that impaired sperm motility is closely linked to dysregulated microRNA expression during spermatogenesis. Seminal plasma exosomes are enriched with diverse microRNAs, which play pivotal roles in modulating sperm motility, the
Zhi‐Jian Zhu, Meng‐Li Cui, Wen‐Jing Yuan, Jia‐Ning Zhang, Shuo Zhang, Xi‐Qiao Yao, Ruo‐Qing Li, Jin‐Feng Li, En‐Zhong Li   +8 more
wiley   +1 more source

Delayed initiation of GnRH antagonist in PCOS patients undergoing IVF: a retrospective cohort study of premature ovulation and embryological outcomes. [PDF]

J Ovarian Res
Peker N, Yücetürk A, Tığlı E, Karaosmanoğlu Ö, Elmas B, Aslan İÖ, Tıraş B.   +6 more
europepmc   +1 more source

IMPROVE 2025: The 3rd International Meeting on Pathway‐Related Obesity: Vision & Evidence

Clinical Obesity, Volume 16, Issue 5, October 2026.
ABSTRACT An international cohort of 161 clinicians and researchers from 19 countries attended the 3rd International Meeting on Pathway‐Related Obesity: Vision & Evidence (IMPROVE) in Prague, Czech Republic, on 2–4 July 2025. The aims of the meeting were to advance understanding of hyperphagia and obesity caused by defects in the melanocortin‐4 receptor
Jesús Argente, Erica L. T. van den Akker, Metin Cetiner, Karine Clément, Elizabeth Forsythe, Alastair Garfield, Peter Kühnen, Gabriel Ángel Martos‐Moreno, David Meeker, Hermann L. Müller, Hanneke M. van Santen, Julia von Schnurbein, Bérénice Segrestin, Tomohiro Tanaka, Manuel Tena‐Sempere, Martin Wabitsch, Stefanie Zorn, I. Sadaf Farooqi   +17 more
wiley   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Effects of a GnRH antagonist on antral follicular development and ovarian hemodynamics in cycling ewes. [PDF]

J Reprod Dev
Bartlewski J, Oliveira MEF, Bartlewski PM.   +2 more
europepmc   +1 more source

Digital Patient Decision Aids for Endometriosis Management: A Scoping Review

Health Expectations, Volume 29, Issue 5, October 2026.
ABSTRACT Background Endometriosis treatment requires women to navigate complex, preference‐sensitive decisions. Patient Decision Aids (PtDAs) help patients make value‐aligned choices. However, the scope and quality of digital PtDAs for endometriosis, and the cap acity of conversational AI platforms to act as PtDAs, remain unclear.
Océane Pittet, Marion Delvallée, Nicola Pluchino, Kevin Selby, Glyn Elwyn, Marie‐Anne Durand   +5 more
wiley   +1 more source

A Personalized FSH Dosing Strategy for Women with Polycystic Ovary Syndrome Undergoing GnRH Antagonist Protocols. [PDF]

Biomedicines
Chen Y, Yang T, Luo Z, Luo L, Zhang Z, Xu Y, Chen M.   +6 more
europepmc   +1 more source

Effects of short‐course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor‐positive, HER2‐negative breast cancer

Histopathology, Volume 89, Issue 4, Page 670-686, October 2026.
Short‐course preoperative endocrine therapy induces histopathological and immunophenotypic changes in oestrogen receptor‐positive, HER2‐negative breast cancer. Proliferative response is independently associated with baseline genomic risk (MammaPrint) and progesterone receptor expression.
Claudia Grosse, Alexandra Grosse, Petar Noack, Caroline Ines Preuss, Heike Kathleen Schwarz, Bruno Schneeweiss, Thomas Gitter, Peter Schrenk, Rupert Langer   +8 more
wiley   +1 more source

Clinical outcomes following GnRH antagonist protocol change to PPOS protocol versus GnRH antagonist protocol in patients with pre-elevated progesterone: a propensity score matching study. [PDF]

J Ovarian Res
Ma J, Tang L, Yang Z, Yuan Z, Su C, Mo H, Meng R, Wen Y.   +7 more
europepmc   +1 more source